{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T23:33:47Z","timestamp":1781307227378,"version":"3.54.1"},"reference-count":68,"publisher":"Akademiai Kiado Zrt.","issue":"3","funder":[{"name":"Thailand Science Research and Innovation (TSRI), Chulabhorn Research Institute","award":["49892\/4759806"],"award-info":[{"award-number":["49892\/4759806"]}]}],"content-domain":{"domain":["akjournals.com"],"crossmark-restriction":true},"short-container-title":["AMicr"],"published-print":{"date-parts":[[2025,10,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:italic>Stenotrophomonas maltophilia<\/jats:italic> has emerged as an opportunistic pathogen that causes life-threatening hospital-acquired infections. This microorganism possesses a diverse array of chromosome-encoded antimicrobial resistance genes, which render it inherently multidrug-resistant (MDR). Its ability to acquire additional antimicrobial resistance via mutations and the horizontal transfer of resistome elements from neighboring microbial communities has further contributed to the development of extensively drug-resistant (XDR) and even pandrug-resistant (PDR) strains. These strains are resistant to routinely used antibiotics, including the first-line drug trimethoprim\/sulfamethoxazole as well as levofloxacin and minocycline. Recently, cefiderocol \u2014 a siderophore-conjugated cephalosporin \u2014 was developed for clinical use. This antibiotic has shown high <jats:italic>in vitro<\/jats:italic> efficacy against clinically relevant MDR gram-negative pathogens. Cefiderocol efficiently transverses the outer membrane of bacteria via iron transport systems and exhibits high stability against \u03b2-lactamases. An injectable form of cefiderocol has received Food and Drug Administration approval for the treatment of complicated urinary tract infections, hospital-acquired bacterial pneumonia, and ventilator-associated bacterial pneumonia caused by drug-resistant gram-negative bacteria. Clinical data on the use of cefiderocol for <jats:italic>S. maltophilia<\/jats:italic> infections remain limited, however, some <jats:italic>in vitro<\/jats:italic>, <jats:italic>in vivo<\/jats:italic>, and case studies have demonstrated its efficacy and successful treatment of MDR <jats:italic>S. maltophilia<\/jats:italic> infections. Given the narrow range of therapeutic options currently available, cefiderocol presents a promising alternative for the effective management of severe <jats:italic>S. maltophilia<\/jats:italic> infections. Nevertheless, the potential for the emergence of resistance remains a significant concern, as emerging evidence suggests that <jats:italic>S. maltophilia<\/jats:italic> may acquire resistance following exposure to this antibiotic.<\/jats:p>","DOI":"10.1556\/030.2025.02676","type":"journal-article","created":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T12:32:01Z","timestamp":1758025921000},"page":"171-179","update-policy":"https:\/\/doi.org\/10.1556\/policypage.crossmark.crossref.2","source":"Crossref","is-referenced-by-count":1,"title":["Cefiderocol as an alternative antibiotic therapy for treating severe Stenotrophomonas maltophilia infections"],"prefix":"10.1556","volume":"72","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8744-4963","authenticated-orcid":true,"given":"Paiboon","family":"Vattanaviboon","sequence":"first","affiliation":[{"name":"Laboratory of Biotechnology, Chulabhorn Research Institute, Bangkok 10210, Thailand"},{"name":"Center of Excellence on Environmental Health and Toxicology (EHT), Office of the Permanent Secretary (OPS), Ministry of Higher Education, Science, Research and Innovation (MHESI), Bangkok 10400, Thailand"},{"name":"Program in Applied Biological Sciences: Environmental Health, Chulabhorn Graduate Institute, Bangkok 10210, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Skorn","family":"Mongkolsuk","sequence":"additional","affiliation":[{"name":"Laboratory of Biotechnology, Chulabhorn Research Institute, Bangkok 10210, Thailand"},{"name":"Center of Excellence on Environmental Health and Toxicology (EHT), Office of the Permanent Secretary (OPS), Ministry of Higher Education, Science, Research and Innovation (MHESI), Bangkok 10400, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nisanart","family":"Charoenlap","sequence":"additional","affiliation":[{"name":"Laboratory of Biotechnology, Chulabhorn Research Institute, Bangkok 10210, Thailand"},{"name":"Center of Excellence on Environmental Health and Toxicology (EHT), Office of the Permanent Secretary (OPS), Ministry of Higher Education, Science, Research and Innovation (MHESI), Bangkok 10400, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"425","reference":[{"key":"B1","series-title":"Clin Microbiol Rev","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00030-19","article-title":"Advances in the microbiology of Stenotrophomonas maltophilia","volume":"34","author":"Brooke JS","year":"2021","unstructured":"Brooke JS. Advances in the microbiology of Stenotrophomonas maltophilia. Clin Microbiol Rev 2021; 34: e0003019. 10.1128\/CMR.00030-19https:\/\/doi.org\/10.1128\/CMR.00030-19"},{"key":"B2","series-title":"Front Med (Lausanne)","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1163439","article-title":"Global prevalence and antibiotic resistance in clinical isolates of Stenotrophomonas maltophilia: a systematic review and meta-analysis","volume":"10","author":"Banar M","year":"2023","unstructured":"Banar M, Sattari-Maraji A, Bayatinejad G, Ebrahimi E, Jabalameli L, Beigverdi R, et\u00a0al. Global prevalence and antibiotic resistance in clinical isolates of Stenotrophomonas maltophilia: a systematic review and meta-analysis. Front Med (Lausanne) 2023; 10: 1163439. 10.3389\/fmed.2023.1163439https:\/\/doi.org\/10.3389\/fmed.2023.1163439"},{"key":"B3","series-title":"Front Microbiol","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.3389\/fmicb.2017.02276","article-title":"Stenotrophomonas maltophilia as an emerging ubiquitous pathogen: looking beyond contemporary antibiotic therapy","volume":"8","author":"Adegoke AA","year":"2017","unstructured":"Adegoke AA, Stenstrom TA, Okoh AI. Stenotrophomonas maltophilia as an emerging ubiquitous pathogen: looking beyond contemporary antibiotic therapy. Front Microbiol 2017; 8: 2276. 10.3389\/fmicb.2017.02276https:\/\/doi.org\/10.3389\/fmicb.2017.02276"},{"key":"B4","series-title":"Genome Biol","doi-asserted-by":"publisher","first-page":"R74","DOI":"10.1186\/gb-2008-9-4-r74","article-title":"The complete genome, comparative and functional analysis of Stenotrophomonas maltophilia reveals an organism heavily shielded by drug resistance determinants","volume":"9","author":"Crossman LC","year":"2008","unstructured":"Crossman LC, Gould VC, Dow JM, Vernikos GS, Okazaki A, Sebaihia M, et\u00a0al. The complete genome, comparative and functional analysis of Stenotrophomonas maltophilia reveals an organism heavily shielded by drug resistance determinants. Genome Biol 2008; 9: R74. 10.1186\/gb-2008-9-4-r74https:\/\/doi.org\/10.1186\/gb-2008-9-4-r74"},{"key":"B5","series-title":"BMC Infect Dis","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1186\/s12879-019-4394-4","article-title":"Risk factors for mortality in patients with Stenotrophomonas maltophilia bacteremia and clinical impact of quinolone-resistant strains","volume":"19","author":"Kim EJ","year":"2019","unstructured":"Kim EJ, Kim YC, Ahn JY, Jeong SJ, Ku NS, Choi JY, et\u00a0al. Risk factors for mortality in patients with Stenotrophomonas maltophilia bacteremia and clinical impact of quinolone-resistant strains. BMC Infect Dis 2019; 19: 754. 10.1186\/s12879-019-4394-4https:\/\/doi.org\/10.1186\/s12879-019-4394-4"},{"key":"B6","series-title":"Antibiotics (Basel)","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics10101226","article-title":"Antimicrobial treatment strategies for Stenotrophomonas maltophilia: a focus on novel therapies","volume":"10","author":"Gibb J","year":"2021","unstructured":"Gibb J, Wong DW. Antimicrobial treatment strategies for Stenotrophomonas maltophilia: a focus on novel therapies. Antibiotics (Basel) 2021; 10. 10.3390\/antibiotics10101226https:\/\/doi.org\/10.3390\/antibiotics10101226"},{"key":"B7","series-title":"Expert Rev Anti Infect Ther","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1080\/14787210.2020.1730178","article-title":"Mechanisms of antimicrobial resistance in Stenotrophomonas maltophilia: a review of current knowledge","volume":"18","author":"Gil-Gil T","year":"2020","unstructured":"Gil-Gil T, Martinez JL, Blanco P. Mechanisms of antimicrobial resistance in Stenotrophomonas maltophilia: a review of current knowledge. Expert Rev Anti Infect Ther 2020; 18: 335\u2013347. 10.1080\/14787210.2020.1730178https:\/\/doi.org\/10.1080\/14787210.2020.1730178"},{"key":"B8","series-title":"Gene Rep","doi-asserted-by":"publisher","DOI":"10.1016\/j.genrep.2023.101857","article-title":"Detection of extended-spectrum \u03b2-lactamases and carbapenemases in clinical isolates of Stenotrophomonas maltophilia in the northeast of Iran","volume":"34","author":"Rizi KS","year":"2024","unstructured":"Rizi KS, Jamehdar SA, Sasan MS, Ghazvini K, Aryan E, Safdari H, et\u00a0al. Detection of extended-spectrum \u03b2-lactamases and carbapenemases in clinical isolates of Stenotrophomonas maltophilia in the northeast of Iran. Gene Rep 2024; 34: 101857. 10.1016\/j.genrep.2023.101857https:\/\/doi.org\/10.1016\/j.genrep.2023.101857"},{"key":"B9","series-title":"Antimicrob Agents Chemother","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1128\/AAC.41.7.1460","article-title":"Sequence analysis and enzyme kinetics of the L2 serine \u03b2-lactamase from Stenotrophomonas maltophilia","volume":"41","author":"Walsh TR","year":"1997","unstructured":"Walsh TR, MacGowan AP, Bennett PM. Sequence analysis and enzyme kinetics of the L2 serine \u03b2-lactamase from Stenotrophomonas maltophilia. Antimicrob Agents Chemother 1997; 41: 1460\u20131464. 10.1128\/AAC.41.7.1460https:\/\/doi.org\/10.1128\/AAC.41.7.1460"},{"key":"B10","series-title":"Biochim Biophys Acta","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0167-4781(94)90011-6","article-title":"Sequence analysis of the L1 metallo-\u03b2-lactamase from Xanthomonas maltophilia","volume":"1218","author":"Walsh TR","year":"1994","unstructured":"Walsh TR, Hall L, Assinder SJ, Nichols WW, Cartwright SJ, MacGowan AP, et\u00a0al. Sequence analysis of the L1 metallo-\u03b2-lactamase from Xanthomonas maltophilia. Biochim Biophys Acta 1994; 1218: 199\u2013201. 10.1016\/0167-4781(94)90011-6https:\/\/doi.org\/10.1016\/0167-4781(94)90011-6"},{"key":"B11","series-title":"J Med Microbiol","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1099\/00222615-35-4-208","article-title":"Susceptibility to beta-lactam antibiotics of mutant strains of Xanthomonas maltophilia with high- and low-level constitutive expression of L1 and L2 beta-lactamases","volume":"35","author":"Akova M","year":"1991","unstructured":"Akova M, Bonfiglio G, Livermore DM. Susceptibility to beta-lactam antibiotics of mutant strains of Xanthomonas maltophilia with high- and low-level constitutive expression of L1 and L2 beta-lactamases. J Med Microbiol 1991; 35: 208\u2013213. 10.1099\/00222615-35-4-208https:\/\/doi.org\/10.1099\/00222615-35-4-208"},{"key":"B12","series-title":"J Biol Chem","doi-asserted-by":"publisher","first-page":"33638","DOI":"10.1074\/jbc.M105550200","article-title":"Novel mechanism of hydrolysis of therapeutic beta-lactams by Stenotrophomonas maltophilia L1 metallo-\u03b2-lactamase","volume":"276","author":"Spencer J","year":"2001","unstructured":"Spencer J, Clarke AR, Walsh TR. Novel mechanism of hydrolysis of therapeutic beta-lactams by Stenotrophomonas maltophilia L1 metallo-\u03b2-lactamase. J Biol Chem 2001; 276: 33638\u201333644. 10.1074\/jbc.M105550200https:\/\/doi.org\/10.1074\/jbc.M105550200"},{"key":"B13","series-title":"Antimicrob Agents Chemother","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1128\/AAC.45.2.413-419.2001","article-title":"Plasmid location and molecular heterogeneity of the L1 and L2 \u03b2-lactamase genes of Stenotrophomonas maltophilia","volume":"45","author":"Avison MB","year":"2001","unstructured":"Avison MB, Higgins CS, von Heldreich CJ, Bennett PM, Walsh TR. Plasmid location and molecular heterogeneity of the L1 and L2 \u03b2-lactamase genes of Stenotrophomonas maltophilia. Antimicrob Agents Chemother 2001; 45: 413\u2013419. 10.1128\/AAC.45.2.413-419.2001https:\/\/doi.org\/10.1128\/AAC.45.2.413-419.2001"},{"key":"B14","series-title":"J Antimicrob Chemother","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1093\/jac\/dki453","article-title":"Beta-lactam resistance and \u03b2-lactamase expression in clinical Stenotrophomonas maltophilia isolates having defined phylogenetic relationships","volume":"57","author":"Gould VC","year":"2006","unstructured":"Gould VC, Okazaki A, Avison MB. Beta-lactam resistance and \u03b2-lactamase expression in clinical Stenotrophomonas maltophilia isolates having defined phylogenetic relationships. J Antimicrob Chemother 2006; 57: 199\u2013203. 10.1093\/jac\/dki453https:\/\/doi.org\/10.1093\/jac\/dki453"},{"key":"B15","series-title":"Front Microbiol","doi-asserted-by":"publisher","first-page":"658","DOI":"10.3389\/fmicb.2015.00658","article-title":"Antibiotic resistance in the opportunistic pathogen Stenotrophomonas maltophilia","volume":"6","author":"Sanchez MB","year":"2015","unstructured":"Sanchez MB. Antibiotic resistance in the opportunistic pathogen Stenotrophomonas maltophilia. Front Microbiol 2015; 6: 658. 10.3389\/fmicb.2015.00658https:\/\/doi.org\/10.3389\/fmicb.2015.00658"},{"key":"B16","series-title":"Acta Microbiol Immunol Hung","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1556\/030.2025.02578","article-title":"Efflux pump systems as keys contributors to multidrug resistanc in Stenotrophomonas maltophilia: physiological roles and gene regulation","volume":"72","author":"Vattanaviboon P","year":"2025","unstructured":"Vattanaviboon P, Dulyayangkul P, Mongkolsuk S, Charoenlap N. Efflux pump systems as keys contributors to multidrug resistanc in Stenotrophomonas maltophilia: physiological roles and gene regulation. Acta Microbiol Immunol Hung 2025; 72: 81\u201392. 10.1556\/030.2025.02578https:\/\/doi.org\/10.1556\/030.2025.02578"},{"key":"B17","series-title":"Antibiotics (Basel)","doi-asserted-by":"publisher","first-page":"550","DOI":"10.3390\/antibiotics14060550","article-title":"Mutation of smeRv renders Stenotrophomonas maltophilia resistant to the first-line antibiotics trimethoprim-sulfamethoxazole and levofloxacin","volume":"14","author":"Boonyong N","year":"2025","unstructured":"Boonyong N, Charoenlap N, Tipanyo P, Grittanaanun P, Mongkolsuk S, Vattanaviboon P. Mutation of smeRv renders Stenotrophomonas maltophilia resistant to the first-line antibiotics trimethoprim-sulfamethoxazole and levofloxacin. Antibiotics (Basel) 2025; 14: 550. 10.3390\/antibiotics14060550https:\/\/doi.org\/10.3390\/antibiotics14060550"},{"key":"B18","series-title":"J Antimicrob Chemother","doi-asserted-by":"publisher","first-page":"3221","DOI":"10.1093\/jac\/dkz326","article-title":"Mechanisms and phenotypic consequences of acquisition of tigecycline resistance by Stenotrophomonas maltophilia","volume":"74","author":"Blanco P","year":"2019","unstructured":"Blanco P, Corona F, Martinez JL. Mechanisms and phenotypic consequences of acquisition of tigecycline resistance by Stenotrophomonas maltophilia. J Antimicrob Chemother 2019; 74: 3221\u20133230. 10.1093\/jac\/dkz326https:\/\/doi.org\/10.1093\/jac\/dkz326"},{"key":"B19","series-title":"Antimicrob Agents Chemother","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1128\/AAC.00496-09","article-title":"SmQnr contributes to intrinsic resistance to quinolones in Stenotrophomonas maltophilia","volume":"54","author":"Sanchez MB","year":"2010","unstructured":"Sanchez MB, Martinez JL. SmQnr contributes to intrinsic resistance to quinolones in Stenotrophomonas maltophilia. Antimicrob Agents Chemother 2010; 54: 580\u2013581. 10.1128\/AAC.00496-09https:\/\/doi.org\/10.1128\/AAC.00496-09"},{"key":"B20","series-title":"Lancet","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S0140-6736(97)07322-4","article-title":"Quinolone resistance from a transferable plasmid","volume":"351","author":"Martinez-Martinez L","year":"1998","unstructured":"Martinez-Martinez L, Pascual A, Jacoby GA. Quinolone resistance from a transferable plasmid. Lancet 1998; 351: 797\u2013799. 10.1016\/S0140-6736(97)07322-4https:\/\/doi.org\/10.1016\/S0140-6736(97)07322-4"},{"key":"B21","series-title":"BMC Microbiol","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/1471-2180-8-148","article-title":"Predictive analysis of transmissible quinolone resistance indicates Stenotrophomonas maltophilia as a potential source of a novel family of Qnr determinants","volume":"8","author":"Sanchez MB","year":"2008","unstructured":"Sanchez MB, Hernandez A, Rodriguez-Martinez JM, Martinez-Martinez L, Martinez JL. Predictive analysis of transmissible quinolone resistance indicates Stenotrophomonas maltophilia as a potential source of a novel family of Qnr determinants. BMC Microbiol 2008; 8: 148. 10.1186\/1471-2180-8-148https:\/\/doi.org\/10.1186\/1471-2180-8-148"},{"key":"B22","series-title":"Antimicrob Agents Chemother","doi-asserted-by":"publisher","first-page":"3823","DOI":"10.1128\/AAC.00026-08","article-title":"Smqnr, a new chromosome-carried quinolone resistance gene in Stenotrophomonas maltophilia","volume":"52","author":"Shimizu K","year":"2008","unstructured":"Shimizu K, Kikuchi K, Sasaki T, Takahashi N, Ohtsuka M, Ono Y, et\u00a0al. Smqnr, a new chromosome-carried quinolone resistance gene in Stenotrophomonas maltophilia. Antimicrob Agents Chemother 2008; 52: 3823\u20133825. 10.1128\/AAC.00026-08https:\/\/doi.org\/10.1128\/AAC.00026-08"},{"key":"B23","series-title":"Microb Drug Resist","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1089\/mdr.2018.0216","article-title":"Characterization of acquired antimicrobial resistance genes in environmental Stenotrophomonas maltophilia isolates from Brazil","volume":"25","author":"Furlan JPR","year":"2019","unstructured":"Furlan JPR, Sanchez DG, Gallo IFL, Stehling EG. Characterization of acquired antimicrobial resistance genes in environmental Stenotrophomonas maltophilia isolates from Brazil. Microb Drug Resist 2019; 25: 475\u2013479. 10.1089\/mdr.2018.0216https:\/\/doi.org\/10.1089\/mdr.2018.0216"},{"key":"B24","series-title":"New Microbes New Infect","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.nmni.2015.04.009","article-title":"Prevalence of Smqnr and plasmid-mediated quinolone resistance determinants in clinical isolates of Stenotrophomonas maltophilia from Japan: novel variants of Smqnr","volume":"7","author":"Kanamori H","year":"2015","unstructured":"Kanamori H, Yano H, Tanouchi A, Kakuta R, Endo S, Ichimura S, et\u00a0al. Prevalence of Smqnr and plasmid-mediated quinolone resistance determinants in clinical isolates of Stenotrophomonas maltophilia from Japan: novel variants of Smqnr. New Microbes New Infect 2015; 7: 8\u201314. 10.1016\/j.nmni.2015.04.009https:\/\/doi.org\/10.1016\/j.nmni.2015.04.009"},{"key":"B25","series-title":"Nat Commun","doi-asserted-by":"publisher","first-page":"4031","DOI":"10.1038\/s41467-023-39778-7","article-title":"Molecular mechanism of plasmid-borne resistance to sulfonamide antibiotics","volume":"14","author":"Venkatesan M","year":"2023","unstructured":"Venkatesan M, Fruci M, Verellen LA, Skarina T, Mesa N, Flick R, et\u00a0al. Molecular mechanism of plasmid-borne resistance to sulfonamide antibiotics. Nat Commun 2023; 14: 4031. 10.1038\/s41467-023-39778-7https:\/\/doi.org\/10.1038\/s41467-023-39778-7"},{"key":"B26","series-title":"Arch Intern Med","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1001\/archinte.163.4.402","article-title":"Trimethoprim-sulfamethoxazole revisited","volume":"163","author":"Masters PA","year":"2003","unstructured":"Masters PA, O'Bryan TA, Zurlo J, Miller DQ, Joshi N. Trimethoprim-sulfamethoxazole revisited. Arch Intern Med 2003; 163: 402\u2013410. 10.1001\/archinte.163.4.402https:\/\/doi.org\/10.1001\/archinte.163.4.402"},{"key":"B27","series-title":"Antimicrob Agents Chemother","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1128\/AAC.00800-08","article-title":"Plasmids imparting sulfonamide resistance in Escherichia coli: implications for persistence","volume":"53","author":"Bean DC","year":"2009","unstructured":"Bean DC, Livermore DM, Hall LM. Plasmids imparting sulfonamide resistance in Escherichia coli: implications for persistence. Antimicrob Agents Chemother 2009; 53: 1088\u20131093. 10.1128\/AAC.00800-08https:\/\/doi.org\/10.1128\/AAC.00800-08"},{"key":"B28","series-title":"Lett Appl Microbiol","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1111\/j.1472-765X.2009.02717.x","article-title":"Distribution of integron-associated trimethoprim-sulfamethoxazole resistance determinants among Escherichia coli from humans and food-producing animals","volume":"49","author":"Ho PL","year":"2009","unstructured":"Ho PL, Wong RC, Chow KH, Que TL. Distribution of integron-associated trimethoprim-sulfamethoxazole resistance determinants among Escherichia coli from humans and food-producing animals. Lett Appl Microbiol 2009; 49: 627\u2013634. 10.1111\/j.1472-765X.2009.02717.xhttps:\/\/doi.org\/10.1111\/j.1472-765X.2009.02717.x"},{"key":"B29","series-title":"Int J Antimicrob Agents","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.ijantimicag.2010.10.025","article-title":"Stenotrophomonas maltophilia resistance to trimethoprim\/sulfamethoxazole mediated by acquisition of sul and dfrA genes in a plasmid-mediated class 1 integron","volume":"37","author":"Hu LF","year":"2011","unstructured":"Hu LF, Chang X, Ye Y, Wang ZX, Shao YB, Shi W, et\u00a0al. Stenotrophomonas maltophilia resistance to trimethoprim\/sulfamethoxazole mediated by acquisition of sul and dfrA genes in a plasmid-mediated class 1 integron. Int J Antimicrob Agents 2011; 37: 230\u2013234. 10.1016\/j.ijantimicag.2010.10.025https:\/\/doi.org\/10.1016\/j.ijantimicag.2010.10.025"},{"key":"B30","series-title":"Jundishapur J Microbiol","doi-asserted-by":"publisher","DOI":"10.5812\/jjm.13975","article-title":"Antibiogram of Stenotrophomonas maltophilia isolated from Nkonkobe Municipality, Eastern Cape Province, South Africa","volume":"8","author":"Adegoke AA","year":"2015","unstructured":"Adegoke AA, Okoh AI. Antibiogram of Stenotrophomonas maltophilia isolated from Nkonkobe Municipality, Eastern Cape Province, South Africa. Jundishapur J Microbiol 2015; 8: e13975. 10.5812\/jjm.13975https:\/\/doi.org\/10.5812\/jjm.13975"},{"key":"B31","series-title":"J Glob Antimicrob Resist","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.jgar.2023.02.018","article-title":"Global prevalence and distribution of antibiotic resistance among clinical isolates of Stenotrophomonas maltophilia: a systematic review and meta-analysis","volume":"34","author":"Dadashi M","year":"2023","unstructured":"Dadashi M, Hajikhani B, Nazarinejad N, Noorisepehr N, Yazdani S, Hashemi A, et\u00a0al. Global prevalence and distribution of antibiotic resistance among clinical isolates of Stenotrophomonas maltophilia: a systematic review and meta-analysis. J Glob Antimicrob Resist 2023; 34: 253\u2013267. 10.1016\/j.jgar.2023.02.018https:\/\/doi.org\/10.1016\/j.jgar.2023.02.018"},{"key":"B32","series-title":"Nat Rev Microbiol","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/s41579-019-0284-4","article-title":"Bacterial siderophores in community and host interactions","volume":"18","author":"Kramer J","year":"2020","unstructured":"Kramer J, Ozkaya O, Kummerli R. Bacterial siderophores in community and host interactions. Nat Rev Microbiol 2020; 18: 152\u2013163. 10.1038\/s41579-019-0284-4https:\/\/doi.org\/10.1038\/s41579-019-0284-4"},{"key":"B33","series-title":"J Bacteriol","doi-asserted-by":"publisher","DOI":"10.1128\/jb.00035-23","article-title":"Energization of outer membrane transport by the ExbB ExbD molecular motor","volume":"205","author":"Braun V","year":"2023","unstructured":"Braun V, Ratliff AC, Celia H, Buchanan SK. Energization of outer membrane transport by the ExbB ExbD molecular motor. J Bacteriol 2023; 205: e0003523. 10.1128\/jb.00035-23https:\/\/doi.org\/10.1128\/jb.00035-23"},{"key":"B34","series-title":"Life (Basel)","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.3390\/life13071427","article-title":"An overview of cefiderocol's therapeutic potential and underlying resistance mechanisms","volume":"13","author":"Domingues S","year":"2023","unstructured":"Domingues S, Lima T, Saavedra MJ, Da Silva GJ. An overview of cefiderocol's therapeutic potential and underlying resistance mechanisms. Life (Basel) 2023; 13: 1427. 10.3390\/life13071427https:\/\/doi.org\/10.3390\/life13071427"},{"key":"B35","series-title":"Clin Infect Dis","doi-asserted-by":"publisher","first-page":"S529","DOI":"10.1093\/cid\/ciz825","article-title":"The role of iron and siderophores in infection, and the development of siderophore antibiotics","volume":"69","author":"Page MGP","year":"2019","unstructured":"Page MGP. The role of iron and siderophores in infection, and the development of siderophore antibiotics. Clin Infect Dis 2019; 69: S529\u2013S537. 10.1093\/cid\/ciz825https:\/\/doi.org\/10.1093\/cid\/ciz825"},{"key":"B36","series-title":"Biochemistry","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1021\/acs.biochem.4c00276","article-title":"Siderophores: a case study in translational chemical biology","volume":"63","author":"LeBlanc AR","year":"2024","unstructured":"LeBlanc AR, Wuest WM. Siderophores: a case study in translational chemical biology. Biochemistry 2024; 63: 1877\u20131891. 10.1021\/acs.biochem.4c00276https:\/\/doi.org\/10.1021\/acs.biochem.4c00276"},{"key":"B37","series-title":"Microbiology (Reading)","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1099\/mic.0.000545","article-title":"Stenotrophomonas maltophilia produces an EntC-dependent catecholate siderophore that is distinct from enterobactin","volume":"163","author":"Nas MY","year":"2017","unstructured":"Nas MY, Cianciotto NP. Stenotrophomonas maltophilia produces an EntC-dependent catecholate siderophore that is distinct from enterobactin. Microbiology (Reading) 2017; 163: 1590\u20131603. 10.1099\/mic.0.000545https:\/\/doi.org\/10.1099\/mic.0.000545"},{"key":"B38","series-title":"Adv Ther","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1007\/s12325-025-03147-1","article-title":"Pharmacokinetic, pharmacokinetic\/pharmacodynamic, and safety investigations of cefiderocol in chinese healthy subjects","volume":"42","author":"Zhang C","year":"2025","unstructured":"Zhang C, Yu S, Li S, Wu X, Wei Q, He J, et\u00a0al. Pharmacokinetic, pharmacokinetic\/pharmacodynamic, and safety investigations of cefiderocol in chinese healthy subjects. Adv Ther 2025; 42: 2285\u20132297. 10.1007\/s12325-025-03147-1https:\/\/doi.org\/10.1007\/s12325-025-03147-1"},{"key":"B39","series-title":"J Clin Pharmacol","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1002\/jcph.841","article-title":"Cefiderocol, a siderophore cephalosporin for gram-negative bacterial infections: pharmacokinetics and safety in subjects with renal impairment","volume":"57","author":"Katsube T","year":"2017","unstructured":"Katsube T, Echols R, Arjona Ferreira JC, Krenz HK, Berg JK, Galloway C. Cefiderocol, a siderophore cephalosporin for gram-negative bacterial infections: pharmacokinetics and safety in subjects with renal impairment. J Clin Pharmacol 2017; 57: 584\u2013591. 10.1002\/jcph.841https:\/\/doi.org\/10.1002\/jcph.841"},{"key":"B40","series-title":"Antimicrob Agents Chemother","doi-asserted-by":"publisher","first-page":"4384","DOI":"10.1128\/AAC.03098-15","article-title":"Stability of novel siderophore cephalosporin S-649266 against clinically relevant carbapenemases","volume":"60","author":"Ito-Horiyama T","year":"2016","unstructured":"Ito-Horiyama T, Ishii Y, Ito A, Sato T, Nakamura R, Fukuhara N, et\u00a0al. Stability of novel siderophore cephalosporin S-649266 against clinically relevant carbapenemases. Antimicrob Agents Chemother 2016; 60: 4384\u20134386. 10.1128\/AAC.03098-15https:\/\/doi.org\/10.1128\/AAC.03098-15"},{"key":"B41","series-title":"Drug Resist Updat","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2023.101034","article-title":"Cefiderocol: clinical application and emergence of resistance","volume":"72","author":"Wang L","year":"2024","unstructured":"Wang L, Zhu J, Chen L, Du H. Cefiderocol: clinical application and emergence of resistance. Drug Resist Updat 2024; 72: 101034. 10.1016\/j.drup.2023.101034https:\/\/doi.org\/10.1016\/j.drup.2023.101034"},{"key":"B42","series-title":"FEMS Microbiol Rev","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1111\/j.1574-6976.2008.00105.x","article-title":"The penicillin-binding proteins: structure and role in peptidoglycan biosynthesis","volume":"32","author":"Sauvage E","year":"2008","unstructured":"Sauvage E, Kerff F, Terrak M, Ayala JA, Charlier P. The penicillin-binding proteins: structure and role in peptidoglycan biosynthesis. FEMS Microbiol Rev 2008; 32: 234\u2013258. 10.1111\/j.1574-6976.2008.00105.xhttps:\/\/doi.org\/10.1111\/j.1574-6976.2008.00105.x"},{"key":"B43","series-title":"Eur J Med Chem","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.ejmech.2018.06.014","article-title":"Cefiderocol (S-649266), a new siderophore cephalosporin exhibiting potent activities against Pseudomonas aeruginosa and other gram-negative pathogens including multi-drug resistant bacteria: structure activity relationship","volume":"155","author":"Aoki T","year":"2018","unstructured":"Aoki T, Yoshizawa H, Yamawaki K, Yokoo K, Sato J, Hisakawa S, et\u00a0al. Cefiderocol (S-649266), a new siderophore cephalosporin exhibiting potent activities against Pseudomonas aeruginosa and other gram-negative pathogens including multi-drug resistant bacteria: structure activity relationship. Eur J Med Chem 2018; 155: 847\u2013868. 10.1016\/j.ejmech.2018.06.014https:\/\/doi.org\/10.1016\/j.ejmech.2018.06.014"},{"key":"B44","series-title":"Clin Infect Dis","doi-asserted-by":"publisher","first-page":"e1103","DOI":"10.1093\/cid\/ciaa1799","article-title":"US Food and Drug Administration (FDA): Benefit-risk considerations for cefiderocol (Fetroja)","volume":"72","author":"Naseer S","year":"2021","unstructured":"Naseer S, Weinstein EA, Rubin DB, Suvarna K, Wei X, Higgins K, et\u00a0al. US Food and Drug Administration (FDA): Benefit-risk considerations for cefiderocol (Fetroja). Clin Infect Dis 2021; 72: e1103\u2013e1111. 10.1093\/cid\/ciaa1799https:\/\/doi.org\/10.1093\/cid\/ciaa1799"},{"key":"B45","series-title":"J Infect","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2024.106376","article-title":"Real-world multicentre study of cefiderocol treatment of immunocompromised patients with infections caused by multidrug-resistant Gram-negative bacteria: CEFI-ID","volume":"90","author":"Soueges S","year":"2025","unstructured":"Soueges S, Faure E, Parize P, Lanternier-Dessap F, Lecuyer H, Huynh A, et\u00a0al. Real-world multicentre study of cefiderocol treatment of immunocompromised patients with infections caused by multidrug-resistant Gram-negative bacteria: CEFI-ID. J Infect 2025; 90: 106376. 10.1016\/j.jinf.2024.106376https:\/\/doi.org\/10.1016\/j.jinf.2024.106376"},{"key":"B46","series-title":"Antimicrob Agents Chemother","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02031-18","article-title":"In vivo pharmacodynamic study of cefiderocol, a novel parenteral siderophore cephalosporin, in murine thigh and lung infection models","volume":"63","author":"Nakamura R","year":"2019","unstructured":"Nakamura R, Ito-Horiyama T, Takemura M, Toba S, Matsumoto S, Ikehara T, et\u00a0al. In vivo pharmacodynamic study of cefiderocol, a novel parenteral siderophore cephalosporin, in murine thigh and lung infection models. Antimicrob Agents Chemother 2019; 63. 10.1128\/AAC.02031-18https:\/\/doi.org\/10.1128\/AAC.02031-18"},{"key":"B47","series-title":"Antimicrob Agents Chemother","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01437-20","article-title":"Population pharmacokinetic and pharmacokinetic\/pharmacodynamic analyses of cefiderocol, a parenteral siderophore cephalosporin, in patients with pneumonia, bloodstream infection\/sepsis, or complicated urinary tract infection","volume":"65","author":"Kawaguchi N","year":"2021","unstructured":"Kawaguchi N, Katsube T, Echols R, Wajima T. Population pharmacokinetic and pharmacokinetic\/pharmacodynamic analyses of cefiderocol, a parenteral siderophore cephalosporin, in patients with pneumonia, bloodstream infection\/sepsis, or complicated urinary tract infection. Antimicrob Agents Chemother 2021; 65. 10.1128\/AAC.01437-20https:\/\/doi.org\/10.1128\/AAC.01437-20"},{"key":"B48","series-title":"Int J Antimicrob Agents","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.ijantimicag.2018.11.007","article-title":"In vitro activity of cefiderocol, a siderophore cephalosporin, against Gram-negative bacilli isolated by clinical laboratories in North America and Europe in 2015-2016: SIDERO-WT-2015","volume":"53","author":"Karlowsky JA","year":"2019","unstructured":"Karlowsky JA, Hackel MA, Tsuji M, Yamano Y, Echols R, Sahm DF. In vitro activity of cefiderocol, a siderophore cephalosporin, against Gram-negative bacilli isolated by clinical laboratories in North America and Europe in 2015-2016: SIDERO-WT-2015. Int J Antimicrob Agents 2019; 53: 456\u2013466. 10.1016\/j.ijantimicag.2018.11.007https:\/\/doi.org\/10.1016\/j.ijantimicag.2018.11.007"},{"key":"B49","series-title":"Antimicrob Agents Chemother","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01454-17","article-title":"In vitro antibacterial properties of cefiderocol, a novel siderophore cephalosporin, against Gram-negative bacteria","volume":"62","author":"Ito A","year":"2018","unstructured":"Ito A, Sato T, Ota M, Takemura M, Nishikawa T, Toba S, et\u00a0al. In vitro antibacterial properties of cefiderocol, a novel siderophore cephalosporin, against Gram-negative bacteria. Antimicrob Agents Chemother 2018; 62. 10.1128\/AAC.01454-17https:\/\/doi.org\/10.1128\/AAC.01454-17"},{"key":"B50","series-title":"Performance standards for antimicrobial susceptibility testing, M100","author":"CLSI","year":"2025","unstructured":"CLSI. Performance standards for antimicrobial susceptibility testing, M100, 35th ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2025."},{"key":"B51","article-title":"Guidance document on Stenotrophomonas maltophilia version 2. European Society of clinical microbiology and infectious diseases","author":"EUCAST. European Committee on Antimicrobial Susceptibility Testing (EUCAST)","year":"2024","unstructured":"EUCAST. European Committee on Antimicrobial Susceptibility Testing (EUCAST), Guidance document on Stenotrophomonas maltophilia version 2. European Society of clinical microbiology and infectious diseases. 2024."},{"key":"B52","series-title":"Infect Dis Ther","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1007\/s40121-025-01117-2","article-title":"Cefiderocol for the treatment of nosocomial bloodstream infections caused by Stenotrophomonas maltophilia: a case series and literature review","volume":"14","author":"Vena A","year":"2025","unstructured":"Vena A, Mezzogori L, Castaldo N, Corcione S, Pascale R, Giannella M, et\u00a0al. Cefiderocol for the treatment of nosocomial bloodstream infections caused by Stenotrophomonas maltophilia: a case series and literature review. Infect Dis Ther 2025; 14: 657\u2013669. 10.1007\/s40121-025-01117-2https:\/\/doi.org\/10.1007\/s40121-025-01117-2"},{"key":"B53","series-title":"Int J Antimicrob Agents","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2021.106395","article-title":"Optimised cefiderocol exposures in a successfully treated critically ill patient with polymicrobial Stenotrophomonas maltophilia bacteraemia and pneumonia receiving continuous venovenous haemodiafiltration","volume":"58","author":"Fratoni AJ","year":"2021","unstructured":"Fratoni AJ, Kuti JL, Nicolau DP. Optimised cefiderocol exposures in a successfully treated critically ill patient with polymicrobial Stenotrophomonas maltophilia bacteraemia and pneumonia receiving continuous venovenous haemodiafiltration. Int J Antimicrob Agents 2021; 58: 106395. 10.1016\/j.ijantimicag.2021.106395https:\/\/doi.org\/10.1016\/j.ijantimicag.2021.106395"},{"key":"B54","series-title":"Open Forum Infect Dis","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad174","article-title":"Successful treatment of persistent Stenotrophomonas maltophilia bacteremia with cefiderocol in an infant","volume":"10","author":"Hsu AJ","year":"2023","unstructured":"Hsu AJ, Simner PJ, Bergman Y, Mathers AJ, Tamma PD. Successful treatment of persistent Stenotrophomonas maltophilia bacteremia with cefiderocol in an infant. Open Forum Infect Dis 2023; 10: ofad174. 10.1093\/ofid\/ofad174https:\/\/doi.org\/10.1093\/ofid\/ofad174"},{"key":"B55","series-title":"Antimicrob Agents Chemother","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01381-16","article-title":"Pharmacokinetic\/pharmacodynamic modeling and simulation of cefiderocol, a parenteral siderophore cephalosporin, for dose adjustment based on renal function","volume":"61","author":"Katsube T","year":"2017","unstructured":"Katsube T, Wajima T, Ishibashi T, Arjona Ferreira JC, Echols R. Pharmacokinetic\/pharmacodynamic modeling and simulation of cefiderocol, a parenteral siderophore cephalosporin, for dose adjustment based on renal function. Antimicrob Agents Chemother 2017; 61. 10.1128\/AAC.01381-16https:\/\/doi.org\/10.1128\/AAC.01381-16"},{"key":"B56","series-title":"Antimicrob Agents Chemother","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00559-20","article-title":"Activity of cefiderocol alone and in combination with levofloxacin, minocycline, polymyxin B, or trimethoprim-sulfamethoxazole against multidrug-resistant Stenotrophomonas maltophilia","volume":"64","author":"Biagi M","year":"2020","unstructured":"Biagi M, Vialichka A, Jurkovic M, Wu T, Shajee A, Lee M, et\u00a0al. Activity of cefiderocol alone and in combination with levofloxacin, minocycline, polymyxin B, or trimethoprim-sulfamethoxazole against multidrug-resistant Stenotrophomonas maltophilia. Antimicrob Agents Chemother 2020; 64. 10.1128\/AAC.00559-20https:\/\/doi.org\/10.1128\/AAC.00559-20"},{"key":"B57","series-title":"Ann Hematol","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1007\/s00277-022-05006-3","article-title":"Successful treatment of MDR Stenotrophomonas maltophilia-associated pneumonia with cefiderocol-based regimen in a patient with hematological malignancy","volume":"101","author":"Zappulo E","year":"2022","unstructured":"Zappulo E, Grimaldi F, Paolillo R, Pinchera B, Buonomo AR, Picardi M, et\u00a0al. Successful treatment of MDR Stenotrophomonas maltophilia-associated pneumonia with cefiderocol-based regimen in a patient with hematological malignancy. Ann Hematol 2022; 101: 2805\u20132806. 10.1007\/s00277-022-05006-3https:\/\/doi.org\/10.1007\/s00277-022-05006-3"},{"key":"B58","series-title":"Medicina (Kaunas)","doi-asserted-by":"publisher","DOI":"10.3390\/medicina60010088","article-title":"Stenotrophomonas maltophilia infections in haematological malignancies and hematopoietic stem cell transplantation: a case series including cefiderocol-based regimens","volume":"60","author":"Lupia T","year":"2024","unstructured":"Lupia T, Carnevale-Schianca F, Vita D, Busca A, Caravelli D, Crisa E, et\u00a0al. Stenotrophomonas maltophilia infections in haematological malignancies and hematopoietic stem cell transplantation: a case series including cefiderocol-based regimens. Medicina (Kaunas) 2024; 60. 10.3390\/medicina60010088https:\/\/doi.org\/10.3390\/medicina60010088"},{"key":"B59","series-title":"J Glob Antimicrob Resist","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.jgar.2023.05.013","article-title":"First case of persistent Stenotrophomonas maltophilia bacteraemia due to septic thrombosis successfully treated with a cefiderocol-containing regimen","volume":"34","author":"Medioli F","year":"2023","unstructured":"Medioli F, Casali E, Viscido A, Pistolesi V, Venditti M, Oliva A. First case of persistent Stenotrophomonas maltophilia bacteraemia due to septic thrombosis successfully treated with a cefiderocol-containing regimen. J Glob Antimicrob Resist 2023; 34: 5\u20138. 10.1016\/j.jgar.2023.05.013https:\/\/doi.org\/10.1016\/j.jgar.2023.05.013"},{"key":"B60","series-title":"Curr Opin Infect Dis","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1097\/QCO.0000000000000975","article-title":"Treatment approaches for severe Stenotrophomonas maltophilia infections","volume":"36","author":"Mojica MF","year":"2023","unstructured":"Mojica MF, Bonomo RA, van Duin D. Treatment approaches for severe Stenotrophomonas maltophilia infections. Curr Opin Infect Dis 2023; 36: 572\u2013584. 10.1097\/QCO.0000000000000975https:\/\/doi.org\/10.1097\/QCO.0000000000000975"},{"key":"B61","series-title":"Clin Infect Dis","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1093\/cid\/ciab1013","article-title":"Infectious Diseases Society of America Guidance on the treatment of AmpC \u03b2-Lactamase-producing Enterobacterales, carbapenem-resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia infections","volume":"74","author":"Tamma PD","year":"2022","unstructured":"Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America Guidance on the treatment of AmpC \u03b2-Lactamase-producing Enterobacterales, carbapenem-resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia infections. Clin Infect Dis 2022; 74: 2089\u20132114. 10.1093\/cid\/ciab1013https:\/\/doi.org\/10.1093\/cid\/ciab1013"},{"issue":"Suppl 1","key":"B62","series-title":"Rev Esp Quimioter","doi-asserted-by":"publisher","first-page":"46","DOI":"10.37201\/req\/s01.11.2023","article-title":"Treatment guidelines for multidrug-resistant Gram-negative microorganisms","volume":"36","author":"Canton R","year":"2023","unstructured":"Canton R, Ruiz-Garbajosa P. Treatment guidelines for multidrug-resistant Gram-negative microorganisms. Rev Esp Quimioter 2023; 36(Suppl 1): 46\u201351. 10.37201\/req\/s01.11.2023https:\/\/doi.org\/10.37201\/req\/s01.11.2023"},{"key":"B63","article-title":"(cefiderocol) for injection. Highlights of prescribing information","author":"Fetroja","unstructured":"Fetroja. (cefiderocol) for injection. Highlights of prescribing information. Reference ID: 4520218, revised: 11\/2019 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/209445s000lbl.pdf."},{"key":"B64","series-title":"Eur J Clin Microbiol Infect Dis","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-025-05108-6","article-title":"Effectiveness and safety of cefiderocol treatment in patients with Gram-negative bacterial infections in Spain in the early access programme: results of the PERSEUS study","author":"Torre-Cisneros J","year":"2025","unstructured":"Torre-Cisneros J, Almirante B, Martos CF, Rascado P, Lleti MS, Sanchez-Garcia M, et\u00a0al. Effectiveness and safety of cefiderocol treatment in patients with Gram-negative bacterial infections in Spain in the early access programme: results of the PERSEUS study. Eur J Clin Microbiol Infect Dis 2025. 10.1007\/s10096-025-05108-6https:\/\/doi.org\/10.1007\/s10096-025-05108-6"},{"key":"B65","series-title":"J Antimicrob Chemother","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.1093\/jac\/dkab221","article-title":"Discrepancy in sustained efficacy and resistance emergence under human-simulated exposure of cefiderocol against Stenotrophomonas maltophilia between in vitro chemostat and in vivo murine infection models","volume":"76","author":"Gill CM","year":"2021","unstructured":"Gill CM, Abdelraouf K, Oota M, Nakamura R, Kuroiwa M, Gahara Y, et\u00a0al. Discrepancy in sustained efficacy and resistance emergence under human-simulated exposure of cefiderocol against Stenotrophomonas maltophilia between in vitro chemostat and in vivo murine infection models. J Antimicrob Chemother 2021; 76: 2615\u20132621. 10.1093\/jac\/dkab221https:\/\/doi.org\/10.1093\/jac\/dkab221"},{"key":"B66","series-title":"JAC Antimicrob Resist","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlac011","article-title":"Evolution of cefiderocol resistance in Stenotrophomonas maltophilia using in vitro serial passage techniques","volume":"4","author":"Werth BJ","year":"2022","unstructured":"Werth BJ, Ashford NK, Penewit K, Waalkes A, Holmes EA, Bryan A, et\u00a0al. Evolution of cefiderocol resistance in Stenotrophomonas maltophilia using in vitro serial passage techniques. JAC Antimicrob Resist 2022; 4: dlac011. 10.1093\/jacamr\/dlac011https:\/\/doi.org\/10.1093\/jacamr\/dlac011"},{"key":"B67","series-title":"Antibiotics (Basel)","doi-asserted-by":"publisher","first-page":"723","DOI":"10.3390\/antibiotics11060723","article-title":"Cefiderocol: systematic review of mechanisms of resistance, heteroresistance and in vivo emergence of resistance","volume":"11","author":"Karakonstantis S","year":"2022","unstructured":"Karakonstantis S, Rousaki M, Kritsotakis EI. Cefiderocol: systematic review of mechanisms of resistance, heteroresistance and in vivo emergence of resistance. Antibiotics (Basel) 2022; 11: 723. 10.3390\/antibiotics11060723https:\/\/doi.org\/10.3390\/antibiotics11060723"},{"key":"B68","series-title":"J Antimicrob Chemother","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1093\/jac\/dkab479","article-title":"Role of AxyABM overexpression in acquired resistance in Achromobacter xylosoxidans","volume":"77","author":"Magallon A","year":"2022","unstructured":"Magallon A, Amoureux L, Garrigos T, Sonois M, Varin V, Neuwirth C, et\u00a0al. Role of AxyABM overexpression in acquired resistance in Achromobacter xylosoxidans. J Antimicrob Chemother 2022; 77: 926\u2013929. 10.1093\/jac\/dkab479https:\/\/doi.org\/10.1093\/jac\/dkab479"}],"container-title":["Acta Microbiologica et Immunologica Hungarica"],"original-title":[],"link":[{"URL":"https:\/\/akjournals.com\/view\/journals\/030\/72\/3\/article-p171.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/akjournals.com\/downloadpdf\/journals\/030\/72\/3\/article-p171.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/akjournals.com\/downloadpdf\/journals\/030\/72\/3\/article-p171.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T07:47:01Z","timestamp":1759996021000},"score":1,"resource":{"primary":{"URL":"https:\/\/akjournals.com\/view\/journals\/030\/72\/3\/article-p171.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,9]]},"references-count":68,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.1556\/030.2025.02676","relation":{},"ISSN":["1217-8950","1588-2640"],"issn-type":[{"value":"1217-8950","type":"print"},{"value":"1588-2640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,9]]}}}